Biotech Values

[Mufaso]

LLY - Lilly's Zepbound (tirzepatide) a dual GLP1/GIP agonist is likely not able to meet demand.

Eli Lilly CEO David Ricks on Monday said the company's powerful weight-loss drug Zepbound hit 25,000 new prescriptions per week at the end of December, and that its 2024 supply may not be enough to meet demand.

https://finance.yahoo.com/news/lilly-ceo-says-weight-loss-190200577.html

Novo has to be worried about what will happen to Ozempic/Wegovy sales when LLY's new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany comes online.

https://investor.lilly.com/news-releases/news-release-details/lilly-expand-injectable-manufacturing-capacity-planned-25